Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Agreement with Alexion is JCR’s first international deal for its blood-brain barrier drug delivery technology. Sartoris buys PolyPlus from private equity investors.
Emerging Company Profile: Fatty liver disease has been a hot development area that keeps getting more attention, and one Chinese startup backed by the world’s largest heparin manufacturer is looking to launch a new therapy globally.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.
- Group Purchasing
- Home Infusion
- Other Names / Subsidiaries
- Cytovance Biologics
- Hepalink USA Inc.
- Shenzhen Hepalink Pharmaceutical Co., Ltd
- Shenzhen Arimab Biopharmaceuticals Co., Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.